Physician profile
Robert Rechtin
NPI 1871537373
$4,041.65
in general payments reported to CMS, 2019-2025
25 companies · $56.69 in 2025
The $56.69 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $95.81 · 2021: $514 · 2022: $1,422 · 2023: $1,260 · 2024: $71.65 · 2025: $56.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,089.63 | 2019-2023 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $611.95 | 2020-2025 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $580.32 | 2019-2025 | |
| Novo Nordisk INC | $555.09 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $223.74 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.76 | 2019-2023 | Synjardy, Jardiance |
| Amgen INC. | $124.37 | 2019-2020 | |
| Glaxosmithkline, LLC. | $109.37 | 2019-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $100.89 | 2022-2023 | Gardasil 9, Steglatro, Belsomra |
| Medtronic, INC. | $87.80 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.02 | 2022 | |
| Biogen, INC. | $61.38 | 2021-2022 | |
| Exact Sciences Corporation | $39.18 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $34.30 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $31.18 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $29.99 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $29.75 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $26.34 | 2022 | |
| Abbott Laboratories | $22.01 | 2023 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $17.65 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $15.28 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.70 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $12.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 | |
| Dynavax Technologies Corporation | $7.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rechtin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.